Matches in DBpedia 2014 for { ?s ?p ImmunoGen Inc. (NASDAQ: IMGN) is a global biotechnology company that is engaged in anti-cancer therapeutics. It was founded in 1981 and is headquartered in Waltham, Massachusetts. It has three wholly owned clinical-stage products including IMGN901, IMG853 and IMGN 529. Besides, it applies its proprietary TAP (Targeted Antibody Payload) technology, ADC (antibody-drug conjugate) and Probody-drug conjugate (PDC) to produce anti-cancer compounds. As of 2009, the company owns or licenses a total of 268 worldwide issued patents and 473 patent applications. The company has been collaborating with CytomX, which is an industrial partner of the Institute for Collaborative Biotechnologies, in developing Probody-Drug Conjugates against cancer. Other therapeutic the company developed and owns include Trastuzumab Emtansine and Lorvotuzumab mertansine. The core product of the company is Kadcyla. It was approved by European Union to market in Europe in 2013, which caused $5 million milestone payment to the company. As of March, 2014, the company has a market capitalization of $1.37 billion with an enterprise value of $1.23 billion.. }
Showing items 1 to 1 of
1
with 100 items per page.
- ImmunoGen abstract "ImmunoGen Inc. (NASDAQ: IMGN) is a global biotechnology company that is engaged in anti-cancer therapeutics. It was founded in 1981 and is headquartered in Waltham, Massachusetts. It has three wholly owned clinical-stage products including IMGN901, IMG853 and IMGN 529. Besides, it applies its proprietary TAP (Targeted Antibody Payload) technology, ADC (antibody-drug conjugate) and Probody-drug conjugate (PDC) to produce anti-cancer compounds. As of 2009, the company owns or licenses a total of 268 worldwide issued patents and 473 patent applications. The company has been collaborating with CytomX, which is an industrial partner of the Institute for Collaborative Biotechnologies, in developing Probody-Drug Conjugates against cancer. Other therapeutic the company developed and owns include Trastuzumab Emtansine and Lorvotuzumab mertansine. The core product of the company is Kadcyla. It was approved by European Union to market in Europe in 2013, which caused $5 million milestone payment to the company. As of March, 2014, the company has a market capitalization of $1.37 billion with an enterprise value of $1.23 billion.".